Middle East And Africa Insulin Pens Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Middle East and Africa Insulin Pens Market is segmented into products (disposable insulin pens and cartridges in reusable pens) and geography (Saudi Arabia, Iran, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD million) and volume (in units million) for the above segments.

MEA Insulin Pens Market Size and Share

MEA Insulin Pens Market Summary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

MEA Insulin Pens Market Analysis by Mordor Intelligence

The MEA Insulin Pens Market size is estimated at USD 1.04 billion in 2025, and is expected to reach USD 1.16 billion by 2030, at a CAGR of 2.19% during the forecast period (2025-2030).

The COVID-19 pandemic has substantially impacted the Middle East and Africa Insulin Pens Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and maintain normal blood glucose levels, which led to an increase in the usage of insulin pens.

Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run. Due to the increasing demand for insulin cartridges, most insulin device manufacturing companies have produced reusable insulin pens that are compatible with various insulin manufacturers' cartridges. These insulin cartridges are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on the go. Cartridges that are open do not need to be refrigerated, making storage very easy for consumers.

Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate administration of insulin. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Competitive Landscape

The Middle East and Africa insulin pens market is consolidated in nature due to the presence of only a few major companies operating globally as well as regionally, namely Novo Nordisk, Sanofi, Eli Lilly and Company, Julphar, etc., among others.

MEA Insulin Pens Industry Leaders

  1. Novo Nordisk A/S

  2. Julphar

  3. Biocon

  4. Sanofi

  5. Eli Lilly and Company

  6. *Disclaimer: Major Players sorted in no particular order
MEA Insulin Pens Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • December 2022: Eli Lilly and Company and EVA Pharma announced a collaboration to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people living with type-1 and type-2 diabetes in low- to middle-income countries, most of which are in Africa. Lilly was likely to supply its active pharmaceutical ingredient for insulin at a significantly reduced price to EVA Pharma. Lilly was also expected to provide a technology transfer to enable EVA Pharma to formulate, fill, and finish insulin vials and cartridges, establishing the company as a trusted manufacturer of these lifesaving products in Africa.
  • October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships were in line with the National Strategy for Industry and Advanced Technology and the ICV Program, which aimed to attract investors and manufacturers to the UAE's pharmaceutical and medical equipment sectors, among others. Under a separate MoU, PureHealth and Gulf Pharmaceutical Industries Company were expected to establish the first factory in the Middle East to produce glargine for the treatment of diabetes.

Table of Contents for MEA Insulin Pens Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Disposable Insulin Pens
    • 5.1.2 Cartridges in Reusable Pens
  • 5.2 Geography
    • 5.2.1 Saudi Arabia
    • 5.2.2 Iran
    • 5.2.3 Egypt
    • 5.2.4 Oman
    • 5.2.5 South Africa
    • 5.2.6 Rest of Middle East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 Biocon
    • 7.1.5 Wockhardt
    • 7.1.6 Julphar
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly
    • 7.2.4 Other Company Share Analyses

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

MEA Insulin Pens Market Report Scope

An insulin pen is a device used to inject insulin. Mainly, two types of insulin pens are available: disposable and reusable. The Middle East and Africa insulin pens market is segmented into products (disposable insulin pens and cartridges in reusable pens) and geography (Saudi Arabia, Iran, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD million) and volume (in units million) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Product
Disposable Insulin Pens
Cartridges in Reusable Pens
Geography
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Product Disposable Insulin Pens
Cartridges in Reusable Pens
Geography Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How big is the MEA Insulin Pens Market?

The MEA Insulin Pens Market size is expected to reach USD 1.04 billion in 2025 and grow at a CAGR of 2.19% to reach USD 1.16 billion by 2030.

What is the current MEA Insulin Pens Market size?

In 2025, the MEA Insulin Pens Market size is expected to reach USD 1.04 billion.

Who are the key players in MEA Insulin Pens Market?

Novo Nordisk A/S, Julphar, Biocon, Sanofi and Eli Lilly and Company are the major companies operating in the MEA Insulin Pens Market.

What years does this MEA Insulin Pens Market cover, and what was the market size in 2024?

In 2024, the MEA Insulin Pens Market size was estimated at USD 1.02 billion. The report covers the MEA Insulin Pens Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the MEA Insulin Pens Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on:

MEA Insulin Pens Market Report

Statistics for the 2025 MEA Insulin Pens market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MEA Insulin Pens analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

MEA Insulin Pens Report Snapshots

Compare market size and growth of MEA Insulin Pens Market with other markets in Healthcare Industry

Still interested in your FREE
sample report?

Report Illustration

Complete your form and get your market insights delivered to your inbox

Takes less than 10 seconds